ALDER BIOPHARMACEUTICALS INC ALDR Balance Sheet

Alder biopharmaceuticals inc (ALDR)

Balance Sheet / Quarterly

Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13
Assets
Current assets
Cash and cash equivalents
88,378	126,105	87,865	94,410	115,754	201,956	76,896	87,334	127,789	79,713	116,216	170,632	230,036	178,035	206,492	234,007	407,966	209,910	46,795	57,553	70,257	12,938	23,227
Short-term investments
320,933	348,517	319,504	357,997	192,810	129,005	199,344	243,551	96,692	209,851	235,651	232,757	217,312	125,119	98,680	72,176	20,447	20,352	9,077	9,052	7,329	-	-
Restricted cash
31,300	23,886	5,000	7,500	5,000	2,500	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	113	81	57	91	316
Prepaid expenses and other assets
11,020	3,806	7,440	6,643	7,641	7,281	11,014	17,590	21,221	19,827	40,380	23,682	15,766	16,572	17,029	13,641	13,652	11,342	4,758	7,065	4,137	1,256	1,982
Inventory
-	-	-	-	-	-	-	936	936	936	936	936	936	-	-	-	-	-	-	-	-	-	-
Total current assets
451,672	502,314	419,809	466,550	321,205	340,742	287,254	349,411	246,638	310,327	393,183	428,007	464,050	319,726	322,201	319,824	442,065	241,604	60,743	73,751	81,780	14,285	25,525
Long-term investments
-	-	-	22,277	217,578	246,086	-	-	-	-	-	-	2,759	50,103	75,840	102,009	-	-	-	978	2,686	-	-
Deferred offering costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,316	-
Property and equipment, net
6,403	6,149	6,400	5,396	4,537	5,055	5,630	6,471	6,714	6,776	7,076	6,610	5,232	2,511	1,974	1,309	1,419	1,338	1,160	1,095	1,171	1,046	1,214
Right of use assets
4,480	4,693	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restricted cash
-	-	-	2,500	5,000	7,500	10,000	10,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Investment in unconsolidated entity
-	-	-	-	-	-	222	402	586	716	865	956	1,050	-	-	-	-	-	-	-	-	-	-
Other assets
12	12	30	30	30	30	30	30	30	30	8,030	8,030	1,286	12	12	3,115	12	-	2,456	-	-	-	-
Total assets
462,567	513,168	426,239	496,753	548,350	599,413	303,136	366,314	253,968	317,849	409,154	443,603	474,377	372,352	400,027	426,257	443,496	242,942	64,359	75,824	85,637	16,647	26,739
Liabilities, convertible preferred stock and stockholders’ equity
Current liabilities
Accounts payable
7,722	15,316	8,945	16,231	15,735	12,801	7,471	22,585	19,796	20,300	10,361	5,703	8,372	9,648	4,727	7,733	2,354	2,216	1,911	1,776	2,831	2,135	2,223
Accrued liabilities
41,826	42,687	19,217	12,828	13,720	11,640	15,803	16,013	14,236	9,243	15,437	10,952	7,710	4,867	7,583	6,629	4,211	4,263	2,963	2,472	1,669	1,962	2,128
Accrued dividends on convertible preferred stock
-	1,311	-	1,279	-	1,083	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating lease liability
981	946	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6,323	18,591	18,579	18,717
Deferred rent
-	-	74	78	82	87	92	92	92	92	92	96	85	62	62	156	149	142	135	128	75	31	-
Total current liabilities
50,529	60,260	28,236	30,416	29,537	25,611	23,366	38,690	34,124	29,635	25,890	16,751	16,167	14,577	12,372	14,518	6,714	6,621	5,009	10,699	23,166	22,707	23,068
Long-term operating lease liability
4,061	4,321	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	26,435	31,050	35,607
Long-term deferred rent
-	-	510	514	495	497	495	454	423	455	481	116	143	124	138	72	112	154	193	217	156	84	52
2025 convertible senior notes, net
188,323	185,146	182,104	179,038	176,052	173,197	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Derivative liability
2,800	2,633	1,658	1,658	1,505	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total liabilities
245,716	252,360	212,508	211,626	207,589	199,305	23,861	39,144	34,547	30,090	26,371	16,867	16,310	14,701	12,510	14,590	6,826	6,775	5,202	10,916	49,757	53,841	58,727
Commitments and contingencies
-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Stockholders’ equity
Preferred stock; $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding
-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	0	-	-	-	-
Common stock; $0.0001 par value; 200,000,000 shares authorized; 83,609,492 and 68,410,576 shares issued and outstanding, respectively
8	8	7	7	7	7	7	7	5	5	5	5	5	4	4	4	4	4	3	3	3	0	-
Additional paid-in capital
1,250,629	1,239,411	1,074,963	1,069,392	1,063,943	1,057,900	946,869	940,387	773,071	766,707	761,456	756,410	752,587	613,452	610,390	607,834	605,920	387,758	196,082	194,873	194,497	2,625	2,443
Accumulated deficit
-1,140,283	-1,081,872	-963,938	-883,849	-822,929	-754,540	-667,509	-613,152	-553,587	-478,958	-378,630	-329,739	-294,605	-255,739	-222,376	-196,211	-169,214	-151,559	-136,906	-129,964	-158,610	-151,209	-145,814
Accumulated other comprehensive loss
-49	-494	-1,056	-1,518	-1,355	-969	-92	-72	-68	5	-48	60	80	-66	-501	40	-40	-36	-22	-4	-10	16	9
Total stockholders’ equity
110,305	157,053	109,976	184,032	239,666	302,398	279,275	327,170	219,421	287,759	382,783	426,736	458,067	357,651	387,517	411,667	436,670	236,167	59,157	64,908	35,880	-148,568	-143,362
Total liabilities, convertible preferred stock and stockholders’ equity
462,567	513,168	426,239	496,753	548,350	599,413	303,136	366,314	253,968	317,849	409,154	443,603	474,377	372,352	400,027	426,257	443,496	242,942	64,359	75,824	85,637	16,647	26,739
Class A-1 Convertible Preferred Stock
Class A-1 convertible preferred stock; $0.0001 par value; 10,000,000 shares authorized; 779,776 and 760,753 shares issued and outstanding, respectively; liquidation preference of $107,516 and $104,893, respectively
106,546	103,755	103,755	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	111,374	111,374
Series A-1 Convertible Preferred Stock
Series A-1 convertible preferred stock; $0.0001 par value; 10,000,000 shares authorized; 742,195 shares and no shares issued and outstanding, respectively; liquidation preference of $100,000 and zero, respectively
-	-	-	101,095	101,095	97,710	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-